Investment Rating - The report maintains a "Buy" rating for Leap Motor (9863.HK) and raises the target price to HKD 83.0, indicating a potential upside of 22% from the current price of HKD 68.15 [2][4]. Core Insights - Leap Motor's sales and net profit guidance for the year exceed expectations, with a target of 580,000 to 650,000 vehicles for 2025. The company anticipates significant growth in both domestic and overseas markets, supported by new model launches and partnerships [8]. - The gross margin is expected to improve, with a forecasted annual gross margin of 14%-15% for the year, driven by increased sales volume and better product mix [8]. - The valuation methodology used is a sum-of-the-parts approach, applying a price-to-sales ratio of 1.6x for 2025 sales, leading to the target price of HKD 83.0 [8]. Financial Performance and Forecast - For Q2 2025, Leap Motor reported revenue of RMB 14.23 billion, a year-on-year increase of 166% and a quarter-on-quarter increase of 42%. The gross margin was 13.6%, up 10.8 percentage points year-on-year [12]. - The company achieved a net profit of RMB 163 million in Q2 2025, marking a return to profitability after a loss in the previous quarter [12]. - Revenue projections for 2023 to 2027 show significant growth, with expected revenues of RMB 16.75 billion in 2023, increasing to RMB 108.44 billion by 2027, reflecting a compound annual growth rate [3][9]. Valuation and Market Position - The current market capitalization of Leap Motor is approximately HKD 91.11 billion, with an average trading volume of HKD 472.2 million over the past three months [4]. - The report highlights that Leap Motor's current price-to-sales ratio is 1.1x, suggesting potential for revaluation as the company continues to grow [8]. - The financial forecasts indicate a steady improvement in profitability, with net losses expected to turn into profits by 2025, projecting a net profit of RMB 634 million [3][9].

Investment Rating - The investment rating for the company is "Maintain Buy" [5] Core Views - The company reported a revenue increase of 1.93% year-on-year for the first half of 2025, achieving a total revenue of RMB 41.835 billion. However, the net profit attributable to shareholders decreased by 1.31% year-on-year to RMB 2.516 billion [1][2][3] - The company continues to distribute dividends, proposing a cash dividend of RMB 0.40 per share, totaling RMB 650 million, which accounts for 25.85% of the net profit for the first half of the year [1][3] Financial Performance Summary - Revenue for 2023 is projected at RMB 75.515 billion, with a year-on-year growth rate of 6.7%. For 2024, revenue is expected to decrease slightly to RMB 74.993 billion, followed by a recovery to RMB 77.589 billion in 2025, representing a growth rate of 3.5% [1][4] - The net profit attributable to shareholders is forecasted to decline to RMB 2.835 billion in 2024, with a subsequent increase to RMB 3.071 billion in 2025, reflecting an 8.3% growth rate [1][4] - The company's return on equity (ROE) is expected to decrease from 11.6% in 2023 to 7.9% in 2024, before gradually improving to 8.9% by 2027 [1][4] - The earnings per share (EPS) is projected to decline from RMB 2.49 in 2023 to RMB 1.74 in 2024, with a recovery to RMB 2.45 by 2027 [1][4] Business Segment Performance - The company’s major business segments include large commercial, health products, and traditional Chinese medicine, with respective revenues of RMB 290 billion, RMB 70.23 billion, and RMB 52.41 billion in the first half of 2025. The health segment showed a growth of 7.42%, while the traditional Chinese medicine segment faced a decline of 15.23% [2][3] - The company is focusing on enhancing its traditional channel coverage for health products and collaborating with major restaurant platforms to boost sales [2] Future Outlook - The company is expected to achieve revenues of RMB 775.89 billion, RMB 813.96 billion, and RMB 847.33 billion from 2025 to 2027, with respective growth rates of 3%, 5%, and 4% [4] - The net profit attributable to shareholders is projected to grow to RMB 30.71 billion, RMB 35.66 billion, and RMB 39.80 billion over the same period, with growth rates of 8%, 16%, and 12% respectively [4]

Investment Rating - The report maintains a "Buy" rating for China Resources Beer [5] Core Views - The company continues to achieve high-end product growth, with a historical high gross margin of 48.9% in H1 2025, driven by the high-end strategy and cost savings in raw material procurement [2][4] - The beer business shows balanced growth across regions, with revenue of 23.16 billion RMB in H1 2025, up 2.6% year-on-year, and sales volume of 6.487 million kiloliters, up 2.2% year-on-year [1][2] - The white liquor business faces industry pressure, with revenue declining by 33.7% year-on-year to 0.781 billion RMB in H1 2025, prompting the company to implement management measures to drive development [2] Summary by Sections Beer Business - Revenue reached 23.16 billion RMB in H1 2025, a 2.6% increase year-on-year - Sales volume was 6.487 million kiloliters, up 2.2% year-on-year - Average selling price increased by 0.4% year-on-year - High-end beer products saw significant growth, with premium and above beer sales increasing by 10% year-on-year [1][2] White Liquor Business - Revenue fell to 0.781 billion RMB in H1 2025, a decrease of 33.7% year-on-year - Major single products contributed nearly 80% of revenue - The company is focusing on management initiatives to drive business development [2] Financial Performance - Gross margin reached a historical high of 48.9%, up 2.0 percentage points year-on-year - The beer business gross margin was 48.3%, up 2.5 percentage points year-on-year - The net profit margin increased by 4.4 percentage points year-on-year to 24.2% [2][4] Future Outlook - The company aims to continue its high-end development strategy, with expectations for net profit growth of 27.7%, 6.9%, and 9.2% for 2025, 2026, and 2027, respectively [2][4]

Investment Rating - The investment rating for the company is "Buy" [5] Core Insights - The company reported a revenue of 9.05 billion yuan for the first half of 2025, representing a year-on-year increase of 11.5%. The adjusted EBITDA was 2.34 billion yuan, up 35.2%, with an adjusted EBITDA margin of 25.9%, an increase of 4.5 percentage points year-on-year [2][5] - The core online travel platform business is experiencing rapid growth, with significant contributions from hotel management, which has over 2,700 operating hotels and a pipeline of 1,500 hotels as of Q2 2025. However, the vacation business faced a decline of 8.0% year-on-year due to safety issues in Southeast Asia [2][3] - The user base continues to expand, with annual paying users growing by 10.2% to 252 million, and 69.0% of new paying users coming from non-first-tier cities [3] - The company aims to deepen its core online travel platform business, enhance its international market presence, and strengthen its hotel management business, which is expected to become a second growth curve for the company [3] Financial Projections - The company is projected to achieve net profits of 2.60 billion yuan, 3.24 billion yuan, and 3.90 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 31.9%, 24.3%, and 20.7% [3][4] - Revenue is expected to grow from 11.90 billion yuan in 2023 to 26.38 billion yuan by 2027, with a compound annual growth rate of approximately 14% [4][9] - The earnings per share (EPS) is forecasted to increase from 0.69 yuan in 2023 to 1.67 yuan in 2027, reflecting a positive growth trajectory [4][9]

Investment Rating - The report maintains a "Buy" rating for China Biopharmaceutical (1177.HK) and raises the target price to HKD 9.1, indicating a potential upside of 15% from the current price of HKD 7.91 [5][6]. Core Insights - In 1H25, the adjusted net profit significantly exceeded expectations, primarily benefiting from a doubling of dividend income from Sinovac. The total revenue for 1H25 was approximately RMB 17.57 billion, reflecting a year-on-year increase of 10.7% and a quarter-on-quarter increase of 35.3% [2][3]. - The company reiterated its guidance for double-digit revenue and adjusted net profit growth for the full year, with the oncology segment showing the fastest growth rate among all segments at 24.9% year-on-year [2][3]. Summary by Sections Financial Performance - For 1H25, the company achieved total revenue of RMB 17.57 billion, with adjusted net profit reaching RMB 3.09 billion, marking a year-on-year increase of 101.1% and a quarter-on-quarter increase of 60.7%. The profit margin improved, with gross margin at 82.5% and adjusted net profit margin at 17.6% [2][3]. - The revenue from innovative products accounted for 44.4% of total revenue, with expectations to increase to 50% by the end of the year. The innovative product revenue reached RMB 7.8 billion, growing 27.2% year-on-year [3][4]. Product Development and Market Expansion - The company is expected to finalize its first overseas licensing deal soon, with several research pipelines anticipated to yield data releases shortly. Key products include TQC3721 and TQB2102, among others, which are expected to show promising results in upcoming clinical trials [4][5]. - The management has indicated that the innovative drugs are projected to achieve over 30% revenue growth, supported by new product launches in 2023-2024 [3][4]. Valuation and Forecast - The adjusted net profit estimates for 2025, 2026, and 2027 have been raised to RMB 5.3 billion, RMB 5.8 billion, and RMB 6.5 billion, respectively, due to the inclusion of sustainable BD income and slight adjustments in innovative drug revenue growth [5][6]. - The DCF valuation model, with a WACC of 8.2% and a perpetual growth rate of 3%, supports the new target price of HKD 9.1 [5][6].

Investment Rating - The report maintains a "BUY" rating for the company, with a target price raised from HK$4.9 to HK$10.2, indicating a potential upside of 29% [6][17]. Core Insights - The company reported a 10.7% year-on-year increase in revenue for the first half of 2025, reaching Rmb17.58 billion, and a 12.3% increase in net profit to Rmb3.39 billion. Adjusted net profit, excluding one-off gains, surged by 101.1% to Rmb3.09 billion, surpassing expectations [6][13]. - The gross margin improved by 0.4 percentage points to 82.5%, while the selling, general, and administrative expenses ratio decreased by 0.2 percentage points to 42.9% [6][13]. - R&D expenses rose by 23.6% to Rmb3.19 billion, with an R&D expense ratio of 18.1%. The company has a cash reserve of approximately Rmb30.5 billion and net cash of Rmb18.5 billion as of June 2025 [6][13]. Summary by Sections Financial Performance - Revenue for the first half of 2025 was Rmb17.58 billion, a 10.7% increase year-on-year. Net profit reached Rmb3.39 billion, up 12.3% year-on-year. Adjusted net profit, excluding one-off items, was Rmb3.09 billion, reflecting a 101.1% increase [6][13]. - The company’s gross margin increased to 82.5%, and the SG&A ratio decreased to 42.9% [6][13]. Innovative Product Growth - Sales of innovative products grew by 27% year-on-year to Rmb7.80 billion, contributing 44% to total revenue in the first half of 2025, up from 39% in the same period last year [7][14]. - The company launched two innovative products in the first half of 2025 and expects to increase the number of innovative products to 21 by 2025 and over 35 by 2027 [8][15]. Acquisition and Pipeline Expansion - The acquisition of LaNova Medicines for a net consideration of US$500 million is expected to enhance the company’s R&D capabilities and expand its innovative pipeline [9][16]. - LaNova Medicines has eight clinical-stage products and over 20 pre-clinical assets, with collaborations with major pharmaceutical companies [9][16].

Investment Rating - The report maintains a "Buy" rating for the company [2][9]. Core Insights - In Q2 2025, the company achieved revenue of 4.669 billion yuan, a year-on-year increase of 10.0%, and an adjusted net profit of 775 million yuan, up 18.0% year-on-year. The adjusted net profit margin improved to 16.6% from 15.5% in the same period last year [2][6]. - The company's core OTA business is experiencing steady growth, with significant contributions from hotel management. In Q2, accommodation revenue reached 1.371 billion yuan (+15.2%), transportation revenue was 1.881 billion yuan (+7.9%), and other revenue was 755 million yuan (+27.5%) [6][9]. - The company is expected to see revenue growth of 19.685 billion yuan, 22.668 billion yuan, and 26.018 billion yuan for the years 2025 to 2027, with adjusted net profits of 3.338 billion yuan, 3.920 billion yuan, and 4.615 billion yuan respectively, corresponding to a current PE of 13, 11, and 9 times [2][6]. Summary by Sections Revenue Performance - The company's core OTA business is growing steadily, with accommodation bookings benefiting from a recovery in average room rates and a shift towards higher-quality products. The platform's average daily rate (ADR) has shown positive growth, and the proportion of bookings for three-star hotels has increased by 4 percentage points year-on-year [6][9]. - The hotel management business is emerging as a significant growth driver, with over 2,700 hotels in operation and more than 1,500 in preparation. Q2 revenue growth for this segment exceeded 60%, contributing 25% to other business revenues [6][9]. Profitability - The company's profitability is on an upward trajectory, with the adjusted net profit margin reaching 16.6%, an increase of 1.1 percentage points year-on-year. This improvement is attributed to optimized sales costs and enhanced marketing efficiency [6][9]. - The report highlights that the company is well-positioned to continue improving its profit margins, supported by rising average revenue per user (ARPU) and operational efficiency [6][9]. Market Outlook - The travel industry is expected to maintain long-term growth potential as consumers increasingly seek unique experiences. The company has established a strong competitive moat through its user base, supply chain capabilities, and service efficiency [2][6]. - The report anticipates that the company's marketing strategies and refined subsidies will further enhance profitability, with room for improvement in sales expense ratios and take rates [2][6].

Investment Rating - The investment rating for China Resources Beer is maintained as "Buy" [2][7][17] Core Views - The report highlights that the beer business is experiencing continuous improvement in profit margins, while the liquor business is under pressure due to weak demand [1][7] - The company reported a revenue of HKD 23.942 billion for H1 2025, a year-on-year increase of 0.8%, and a net profit attributable to shareholders of HKD 5.789 billion, up 23.04% year-on-year [7] - The report anticipates a continued increase in net profit margins driven by product structure upgrades and cost advantages in the beer segment [7] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: HKD 38,932 million - 2024: HKD 38,635 million - 2025E: HKD 38,360 million - 2026E: HKD 39,036 million - 2027E: HKD 39,626 million - Net profit attributable to shareholders is forecasted as: - 2023: HKD 5,153 million - 2024: HKD 4,739 million - 2025E: HKD 5,633 million - 2026E: HKD 5,690 million - 2027E: HKD 6,111 million - The report indicates a projected net profit growth of 19% in 2025, followed by 1% and 7% in 2026 and 2027 respectively [6][8] Business Performance - The beer segment achieved a revenue of HKD 23.161 billion in H1 2025, with a year-on-year growth of 2.6% and a sales volume of 6.49 million tons, up 2.2% [7] - The average price per ton of beer was HKD 3,570, reflecting a 0.4% increase year-on-year [7] - The gross margin for the beer business improved to 48.3%, an increase of 2.5 percentage points year-on-year [7] - The liquor business reported a revenue of HKD 781 million in H1 2025, a decline of 33.7% year-on-year, primarily due to weak business demand [7]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company focuses on innovative drug development, particularly in metabolic products, and has a strong cash position to support its R&D activities until 2029 [1] - ASC30, a potential best-in-class GLP-1 small molecule weight loss drug, shows promising clinical data with an average weight reduction of 6.5% after 28 days of oral administration [2] - ASC47, another drug in development, demonstrates the potential for fat loss without muscle loss when used in combination with GLP-1 peptides, with ongoing clinical trials expected to yield data this year [3] Financial Performance and Forecast - The company reported a revenue of 0.01 billion RMB and a net profit of -0.88 billion RMB for the first half of 2025 [1] - The revenue forecast for 2025 is expected to remain at 0.01 billion RMB, with a projected net profit of -4.21 billion RMB, an improvement from previous estimates [4][9] - The estimated earnings per share (EPS) for 2025 is projected at -0.43 RMB [4][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's image product subscription rate continues to improve, driven by AI, leading to an expected increase in gross margin. The adjusted net profit forecast for 2025-2027 has been raised to 889 million, 1.15 billion, and 1.51 billion respectively, corresponding to year-on-year growth rates of 50.7%, 29.7%, and 31.1% [6] - The company reported a revenue of 1.82 billion for H1 2025, a year-on-year increase of 12.3%, which was below Bloomberg's consensus estimate of 24.8% growth. However, the adjusted net profit of 470 million was above expectations, reflecting a strong performance in the image product segment [7] - The company is focusing on AI-driven enhancements and global expansion, with a significant user base in the C-end market and plans to penetrate B-end vertical scenarios [8] Financial Summary and Valuation Metrics - Revenue projections for 2025 are estimated at 3.943 billion, with a year-on-year growth of 18.0%. Adjusted net profit is expected to reach 885 million, reflecting a year-on-year increase of 50.7% [9] - The gross margin is projected to improve to 74.1% by 2025, with a net margin of 22.5% [9] - The company’s EPS is forecasted to be 0.20, 0.26, and 0.34 for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 48.6, 37.4, and 28.5 [9]